Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica

Mayank R. Ajmera, Audra Boscoe, Josephine Mauskopf, Sean D. Candrilli, Michael Levy

Research output: Contribution to journalArticle

Abstract

Background Neuromyelitis optica (NMO) is characterized by unpredictable attacks on the optic nerves and spinal cord, causing accumulations of neurological disability that may lead to blindness and paralysis. We examined comorbidities and health care use among patients with highly active NMO, defined as at least two relapses within 12 months of the patient's first NMO encounter in the database. Methods This retrospective study of a US administrative claims database compared patients with highly active NMO to matched individuals without NMO. All outcomes, including Charlson Comorbidity Index (CCI) score, hospitalizations, and emergency department visits, were measured over the 12-month period following the patient's first NMO encounter in the database. Results A total of 1349 patients with NMO were identified. Of these, 134 had highly active NMO (80% female, mean age 45.6 years) and were matched to 670 non-NMO controls. Patients with highly active NMO had significantly greater comorbidity burden than non-NMO controls (mean CCI score: 4.1 versus 0.6; P < 0.0001) and greater proportions of hospitalization (53.7% versus 4.0%; P < 0.0001) and emergency department visits (60.5% versus 9.7%; P < 0.0001). Conclusions High occurrence of several acute and chronic conditions and extensive health care use highlight the significant medical burden among patients with highly active NMO.

Original languageEnglish (US)
Pages (from-to)96-103
Number of pages8
JournalJournal of the Neurological Sciences
Volume384
DOIs
StatePublished - Jan 15 2018

Keywords

  • Disease burden
  • Neurological disorders
  • Neuromyelitis optica
  • Real-world case-control study

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica'. Together they form a unique fingerprint.

Cite this